Name: RLY-4008; Lirafugratinib

Cat#: EX-A6478

Chemical Structure of RLY-4008:



Chemical Name	N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide

Molecular Weight	509.53	Storage	2 years -20°C powder 6 months -80°C in solvent Away from light
Formula	$C_{28}H_{24}FN_7O_2$		
CAS No.	2549174-42-5	Synonyms	RLY 4008; RLY4008; Lirafugratinib

Target: EGFR
Pathway: JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Solubility (25°C) *	In vitro	DMSO	>50 mg/mL
		Ethanol	N/A
		Water	N/A
	In vivo （should be freshly prepared each time）		

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions:

Mass / Volume / Concentration	1 mg	5 mg	10 mg
1 mM	1.9626 mL	9.8130 mL	19.6259 mL
5 mM	0.3925 mL	1.9626 mL	3.9252 mL
10 mM	0.1963 mL	0.9813 mL	1.9626 mL

*The above data is based on the product molecular weight 509.53.

Biological Activities:

Description	RLY-4008 is an orally active selective inhibitor of FGFR2[1].

References	[1]. Lescarbeau, Andre, et al. Preparation of substituted pyrrolopyrimidines as FGFR inhibitors and methods of making and using the same. Patent WO2022109577.